Corazon Sanders

AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA.

Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou.

Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou.

AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA.

AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA.

AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA.

Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou.

AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA.

Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou.

Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou.

AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA.

AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA.

AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA.